Document Detail

Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
MedLine Citation:
PMID:  20614421     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Persistent patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants. Prostaglandin synthetase inhibitors such as indomethacin promote PDA closure but also have potential side effects. The effect of the prophylactic use of indomethacin, where infants who may not have gone on to develop a symptomatic PDA would be exposed to indomethacin, warrants particular scrutiny.
OBJECTIVES: To determine the effect of prophylactic indomethacin on mortality and morbidity in preterm infants.
SEARCH STRATEGY: The standard search strategy of the Cochrane Neonatal Review Group was used. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 5, 2010), MEDLINE, EMBASE and CINAHL (until April 2010), conference proceedings, and previous reviews.
SELECTION CRITERIA: Randomised or quasi-randomised controlled trials that compared prophylactic indomethacin versus placebo or no drug in preterm infants.
DATA COLLECTION AND ANALYSIS: The standard methods of the Cochrane Neonatal Review Group were used, with separate evaluation of trial quality and data extraction by two review authors.
MAIN RESULTS: Nineteen eligible trials in which 2872 infants participated were identified. Most participants were very low birth weight, but the largest single trial restricted participation to extremely low birth weight infants (N = 1202). The trials were generally of good quality.The incidence of symptomatic PDA [typical relative risk (RR) 0.44, 95% confidence interval (CI) 0.38 to 0.50] and PDA surgical ligation (typical RR 0.51, 95% CI 0.37,0.71) was significantly lower in treated infants. Prophylactic indomethacin also significantly reduced the incidence of severe intraventricular haemorrhage (typical RR 0.66, 95% CI 0.53 to 0.82). Meta-analyses found no evidence of an effect on mortality (typical RR 0.96, 95% CI 0.81 to 1.12) or on a composite of death or severe neurodevelopmental disability assessed at 18 to 36 months old (typical RR 1.02, 95% CI 0.90, 1.15).
AUTHORS' CONCLUSIONS: Prophylactic indomethacin has short-term benefits for preterm infants including a reduction in the incidence of symptomatic PDA, PDA surgical ligation, and severe intraventricular haemorrhage. However, there is no evidence of effect on mortality or neurodevelopment.
Peter W Fowlie; Peter G Davis; William McGuire
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2010-07-07
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2010  
Date Detail:
Created Date:  2010-07-08     Completed Date:  2010-08-11     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD000174     Citation Subset:  IM    
Women & Child Health, Ninewells Hospital and Medical School, Dundee, Scotland, UK, DD1 9SY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Agents / administration & dosage*,  adverse effects
Cerebral Hemorrhage / mortality,  prevention & control
Ductus Arteriosus, Patent / prevention & control*
Indomethacin / administration & dosage*,  adverse effects
Infant, Extremely Low Birth Weight
Infant, Newborn
Infant, Premature, Diseases / mortality*
Infant, Very Low Birth Weight*
Injections, Intravenous
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Cardiovascular Agents; 53-86-1/Indomethacin
Update Of:
Cochrane Database Syst Rev. 2002;(3):CD000174   [PMID:  12137607 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hospitalisation and bed rest for multiple pregnancy.
Next Document:  Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns.